The global Neurological biomarkers market is projected to grow from USD 5.53 billion in 2025 to USD 9.91 billion by 2030, at a CAGR of 10.7%. This growth reflects the accelerating shift toward precision neurology and data-driven clinical decision-making. Amid the growing global burden of neurological disorders, the role of biomarkers in transforming diagnosis and therapeutic development is becoming increasingly critical.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153432005
What is driving this strong market momentum?
The increasing prevalence of neurological conditions such as Alzheimer’s and Parkinson’s diseases is intensifying the demand for early and accurate diagnostic tools. At the same time, rising clinical validation and regulatory acceptance of biomarkers are enabling their broader integration into healthcare systems and research frameworks.
Why are genomic biomarkers gaining significant attention?
The genomic biomarkers segment is expected to be the fastest-growing during the forecast period, fueled by advancements in next-generation sequencing (NGS), declining sequencing costs, and expanding applications in precision medicine. These biomarkers are enhancing risk stratification, enabling early disease detection, and playing a pivotal role in patient selection for clinical trials—ultimately improving therapeutic outcomes and development efficiency.
Who is leading the adoption curve?
Pharmaceutical and biotechnology companies accounted for the largest market share by end user in 2024. Their extensive reliance on biomarkers across drug discovery and development processes—including target validation, patient stratification, and companion diagnostics—is a key growth driver. Increasing investments in neurological drug pipelines and the growing use of biomarker-driven clinical trials are further accelerating adoption across both preclinical and clinical stages.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=153432005
Where are the strongest regional opportunities emerging?
North America continues to dominate the neurological biomarkers market, supported by advanced healthcare infrastructure, strong R&D investments, and the presence of leading industry players. The region’s early adoption of precision medicine and favorable regulatory landscape are facilitating faster biomarker development and commercialization, reinforcing its leadership position.
Who are the key players shaping the competitive landscape?
Prominent companies include Abbott, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories, Inc., Merck KGaA, Johnson & Johnson, Quanterix, and Banyan Biomarkers, Inc.. These organizations are investing heavily in advanced biomarker platforms, strategic collaborations, and precision medicine initiatives to strengthen their market position.